1. Yellow Fever Vaccination of a Primary Vaccinee During Adalimumab Therapy.
- Author
-
Nash, Esther R., Brand, Myron, and Chalkias, Spyridon
- Subjects
- *
YELLOW fever vaccines , *YELLOW fever treatment , *CROHN'S disease , *ADALIMUMAB , *MONOCLONAL antibodies , *PHYSIOLOGY , *DISEASE risk factors - Abstract
In this case report, we describe a 63-year-old female with Crohn's disease since age 16 years, and on adalimumab therapy, who inadvertently received a yellow fever vaccine ( YFV) 4 days before her next dose of adalimumab. She had never received YFV. Her next dose of tumor necrosis factor ( TNF) antagonist was held. She did not report any adverse effects referable to the vaccine. Reverse transcriptase-polymerase chain reaction ( RT-PCR) for yellow fever ( YF) viral RNA on days 12 and 18 postvaccination was negative. Neutralizing antibody to YF virus vaccine was immunoprotective on day 18 following vaccination, which further increased by day 26. A neutralizing antibody obtained 2 years following vaccination also remained immunoprotective. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF